Texas Tech University Health Sciences Center Partners with Deep 6 AI
Texas Tech University Health Sciences Center (TTUHSC) and Deep 6 AI announced a collaboration, collaborating to integrate artificial intelligence (AI) within TTUHSC's electronic medical record (EMR) system.
TTUHSC will use Deep 6 AI to match patients to their clinical trials in real time. This process will allow researchers to find the right patients for their trials, which will reduce the workload on their staff. By using these AI tools, TTUHSC researchers will ultimatey give more patients access to participate in clinical trials and will be able to use any resulting therapies to treat patients.
Deep 6 AI uses natural language processing to search through structured and unstructured EMR data points, such as physician notes, lab reports, outpatient notes, radiology reports, genomics results, and pathology reports, to match patients to the ideal clinical trials. This process simplifies patient recruitment and allows administrators to focus on patient care and managing the trials.
Reference
Texas Tech University Health Sciences Center Partners with Deep 6 AI to Launch an AI Program for Clinical Trials. (2023, August 1). Cision PR Newswire.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
